Universal Ibogaine — Fact Sheet (November 2021)

4 slides from Universal Ibogaine's fact sheet, November 2021

Slide 1: Team and Company Overview
Te) i) UNIVERSAL IBOGAINE TSX-V:IBO Team UNIVERSAL IBOGAINE Dr. Rami Batal, PharmD/PhD Chief Executive Officer Greg Leavens, CPA Chief Financial Officer Dr. lan Rabb Chief Clinics Officer Chief lan Campbell, MBA Chairman (Independant) Dr. Alberto Sola, MD Co-Founder and Director Robert Turner, |CD.D
Slide 2: Share structure and ibogaine background
In # millions. Exercise Price Shares issued and outstanding at August 31, 202] (notes 1) 190.3 Options (brokers and PSQ Directors) Options (UI D & Os) $0.10 ] to 2years 5 years Performance shares - Directors and CEO (based on clinical trials and other targets) n/a n/a 37 Advisors warrants Dec 31,202
Slide 3: Why Universal Ibogaine?
Ve hy UNIVERSALIBOGAINE ? Offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically supervised and regulatory- sanctioned channel to participate in the PSYCHEDELICS space Our ibogaine “biotech” play is inherently “de-risked” due to the real-world data/evidence b
Slide 4: Pre-CTA Meeting timeline
--2021-- Q4 Pre-CTA Meeting CTA Submission NOL, Ph2/HPOC Initiation* *Human proof of concept study (usually aligned with a ph28 (phase) development stage) --2022-- Q4 (Onward) Ph2/HPOC Completion Ph2/HPOC Readout Special Access (or Ph3/pivotal Start) Pre-CTAY Meeting Clinic 3+ Licensing / Franchisin